Loading clinical trials...
Loading clinical trials...
A Phase II, Open Label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib in Monotherapy or in Combination With Anti-PD1 Inhibitor TSR-042 in Recurrent Endometrial Cancer
Conditions
Interventions
Niraparib
TSR-042
Locations
7
Canada
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, Canada
London Regional Cancer Centre
London, Ontario, Canada
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
November 6, 2017
Primary Completion Date
January 5, 2021
Completion Date
December 1, 2025
Last Updated
January 30, 2024
NCT05489211
NCT04657068
NCT04585750
NCT07029399
NCT06975293
NCT07166094
Lead Sponsor
University Health Network, Toronto
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions